Esophageal cancer

Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024

Retrieved on: 
星期五, 五月 24, 2024
Radiation therapy, Peking Union Medical College, EP4, Esophageal cancer, Medicine, ANL, Clinical trial, Tumor microenvironment, Trial of the century, Safety, Neoadjuvant therapy, Macrophage, ASCO, Hospital, Society, CRT, Annual general meeting, Pharmaceutical industry

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will present encouraging preliminary data of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC) at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting to be held in Chicago from May 31 to June 4, 2024.

Key Points: 
  • SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will present encouraging preliminary data of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC) at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting to be held in Chicago from May 31 to June 4, 2024.
  • AN0025 is a selective EP4 inhibitor that demonstrates antitumor activity by modulating the function of macrophages and immunosuppressive myeloid cells in tumor microenvironment.
  • The combination of AN0025 with CRT as neoadjuvant therapy has shown synergistic antitumor efficacy in locally advanced rectal cancer in a prior clinical trial (NCT03152370).
  • The AN0025S0104 study is a single-arm, open-label, multicenter, Phase Ib study comprising a dose escalation phase followed by an expansion phase, aimed at evaluating the safety, tolerability, and feasibility of AN0025 plus dCRT for unresectable locally advanced or locally recurrent EC or esophagogastric junction cancer.

BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

Retrieved on: 
星期四, 五月 16, 2024
Esophageal cancer, University School, Docetaxel, IND, EGFR, Monroe Dunaway Anderson, Drug discovery, Research, PROTAC, Johns Hopkins Hospital, Respiratory disease, International Association, Publication, Internet, PD-1, CSO, MOA, CNS, Cayetano Heredia University, Research institute, Radiation, OS, Research and development, Immunotherapy, Eli Lilly, Lung cancer, Entrepreneurship, Howard Hughes Medical Institute, Radiation therapy, University, RBM39, Protein, NSCLC, MD Anderson Cancer Center, Cancer, Society, Microtubule, Lung, Patient, IIT, HNSCC, Oncology, Therapy, Biomarker, Abstract, Virology, TPD, Pharmaceutical industry

(Moffitt Cancer Center), and Steven Lin, M.D., Ph.D. (MD Anderson Cancer Center), as well as BeyondSpring and SEED Therapeutics management.

Key Points: 
  • (Moffitt Cancer Center), and Steven Lin, M.D., Ph.D. (MD Anderson Cancer Center), as well as BeyondSpring and SEED Therapeutics management.
  • Plinabulin alone or in combination has been well-tolerated in >700 cancer patients in two positive phase 3 studies.
  • Following the plinabulin presentations, Dr. Lan Huang discussed how BeyondSpring’s majority-owned subsidiary, SEED Therapeutics, uses its proprietary TPD platforms to develop “molecular glues” for undruggable targets.
  • Dr. Lin runs a translational research team that evaluates biomarkers for treatment response and disease outcomes after cancer therapy.

Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting

Retrieved on: 
星期四, 五月 23, 2024
Biotechnology, Genetics, Health, Oncology, Patient, Carcinoma, Doctor of Philosophy, Empower, DNA, Esophageal cancer, SAVE, Genetic testing, Colorectal cancer, Recurrence, Presentation, Cancer, Breast cancer, Neoplasm, MD, MRD, Melanoma, Biomarker, ASCO, CRC, Lung cancer, Society, EBC, NTRA, ALTAIR, Annual general meeting, Birth control

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the company, along with its collaborators, will present new data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4, 2024.

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the company, along with its collaborators, will present new data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4, 2024.
  • Minetta Liu, MD, chief medical officer of oncology at Natera, said, “We look forward to sharing new data across cancer types, reflecting Natera's deep clinical pipeline in MRD with results from randomized trials as well as real-world studies.
  • Natera expects to announce topline results for this phase III randomized trial in August 2024.
  • Poster Presentation | Abstract # 518 | Presenter: Yoichi Naito, MD | Breast Cancer
    ctDNA monitoring for breast cancer at high risk of recurrence: Interim analysis of JCOG1204A1
    Poster Presentation | Abstract # 10596 | Presenter: Sarah Lee, MD | Pan-Cancer (Empower)

Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024

Retrieved on: 
星期二, 五月 14, 2024
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Health Technology, Other Science, Medical Devices, Research, Surgery, Science, Stomach, MPH, DDW, ASGE, Organization, Meta-analysis, Treatment, University, Woman, Esophageal cancer, FACG, Barrett's esophagus, FACP, FACS, Division, GI, Abstract, Risk factor, Malignancy, Systematic review, Esophagus, Hepatology, Vaccine

Title: The Tissue Systems Pathology Test Predicts Risk of Malignant Progression in Patients with Barrett's Esophagus: A Systematic Review and Meta-Analysis

Key Points: 
  • Title: The Tissue Systems Pathology Test Predicts Risk of Malignant Progression in Patients with Barrett's Esophagus: A Systematic Review and Meta-Analysis
    Session Title: Barrett's Esophagus and Esophagogastric Junction Neoplasia - Epidemiology, Risk factors, Screening, Surveillance, Treatment and Outcomes
    Title: The Tissue Systems Pathology Test Provides Clinically Actionable Risk-Stratification in Patients with Barrett’s Esophagus: A Multicenter U.S. Clinical Experience
    Session Title: Barrett's Esophagus and Esophagogastric Junction Neoplasia - Epidemiology, Risk factors, Screening, Surveillance, Treatment and Outcomes
    For more information on the above abstracts and the TissueCypher test, visit Castle at booth 3737; a complete list of Castle’s activities at DDW 2024 can be found at https://info.castlebiosciences.com/ddw2024 .
  • Key events include the following:
    Panel discussion to include: Emmanuel Gorospe, M.D., MPH, FACP, FACG, FASGE, GI medical director at Castle Biosciences; Dan Lister, M.D., FACS, FAFS, surgeon and director of the Arkansas Heartburn Treatment Center, and co-founder and president elect of the American Foregut Society; Dr. Farhan Quader, M.D., interventional gastroenterologist at NorthShore University Hospital in Chicago; Sarah Enslin, PA-C, Division of Gastroenterology and Hepatology at the University of Rochester Medical Center Rochester in New York
    Additionally, Castle is collaborating with several organizations, including the ASGE, Esophageal Cancer Action Network, American Muslim Gastroenterologist Network, American Foregut Society and Women in Endoscopy on various educational and networking events taking place throughout the meeting.

WestGene's mRNA Therapeutic Cancer Vaccine Receives FDA Approval

Retrieved on: 
星期五, 五月 10, 2024
Ionization, Patient, Esophageal cancer, IIT, Toxicity, Patent, Nasopharyngeal carcinoma, NPC, Messenger, FDA, Cervical cancer, Malignancy, Breast cancer, Vaccine, Bone marrow, EB, Lipid, Multiple sclerosis, Research, Stomach, Lupus, Cancer, Lung cancer, Liver cancer

CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043.

Key Points: 
  • CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043.
  • This landmark achievement marks the world's first approval of an EB virus-related mRNA therapeutic cancer vaccine.
  • The FDA approval of WGc-043 represents a significant advance in cancer treatment, offering new hope to patients with advanced EB virus-related cancers.
  • EB virus is highly correlated with more than ten malignancies, including nasopharyngeal carcinoma (NPC), natural killer T-cell lymphoma (NKTL), gastric cancer, lung cancer, liver cancer, esophageal cancer, breast cancer, cervical cancer, and autoimmune diseases such as multiple sclerosis and systemic lupus erythematosus.

WestGene's mRNA Therapeutic Cancer Vaccine Receives FDA Approval

Retrieved on: 
星期五, 五月 10, 2024
Ionization, Patient, Esophageal cancer, IIT, Toxicity, Patent, Nasopharyngeal carcinoma, NPC, Messenger, FDA, Cervical cancer, Malignancy, Breast cancer, Vaccine, Bone marrow, EB, Lipid, Multiple sclerosis, Research, Stomach, Lupus, Cancer, Lung cancer, Multimedia, Liver cancer

CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043.

Key Points: 
  • CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043.
  • This landmark achievement marks the world's first approval of an EB virus-related mRNA therapeutic cancer vaccine.
  • The FDA approval of WGc-043 represents a significant advance in cancer treatment, offering new hope to patients with advanced EB virus-related cancers.
  • EB virus is highly correlated with more than ten malignancies, including nasopharyngeal carcinoma (NPC), natural killer T-cell lymphoma (NKTL), gastric cancer, lung cancer, liver cancer, esophageal cancer, breast cancer, cervical cancer, and autoimmune diseases such as multiple sclerosis and systemic lupus erythematosus.

ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives. - Updated

Retrieved on: 
星期四, 五月 9, 2024
Project, FDA, Sale, Mayo Clinic, Genomics, Health, Nebula Genomics, Research, Insurance, Collection, Water, Consultant, Genetic testing, Development, Public expenditure, Automation, DNA, SNP, Esophageal cancer, Data, Omicron, Algorithm, Three Months, Patient, CPT, Acquisition, Prophase, Food, Diagnosis, Immunity, Nebula, HRSA, Absorption, COVID-19, Engineering, Medical device

Garden City, NY, May 09, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported its financial and operational results for the three months ended March 31, 2024.

Key Points: 
  • The three months ended March 31, 2024, marked a continuation of the transformation of ProPhase Labs.
  • Diagnostic services costs for the three months ended March 31, 2024 were zero compared to $1.2 million for the three months ended March 31, 2023.
  • Research and development costs for the three months ended March 31, 2024 were $272,000 as compared to $144,000 for the three months ended March 31, 2023.
  • Diluted loss and earnings per share for the three months ended March 31, 2024 and 2023 were $(0.07) and $0.03, respectively.

ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives.

Retrieved on: 
星期四, 五月 9, 2024
Project, FDA, Sale, Mayo Clinic, Genomics, Health, Nebula Genomics, Research, Insurance, Collection, Water, Consultant, Genetic testing, Development, Public expenditure, Automation, DNA, SNP, Esophageal cancer, Data, Omicron, Algorithm, Three Months, Patient, CPT, Acquisition, Prophase, Food, Diagnosis, Immunity, Nebula, HRSA, Absorption, COVID-19, Engineering

Garden City, NY, May 09, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported its financial and operational results for the three months ended March 31, 2024.

Key Points: 
  • The three months ended March 31, 2024, marked a continuation of the transformation of ProPhase Labs.
  • Diagnostic services costs for the three months ended March 31, 2024 were zero compared to $1.2 million for the three months ended March 31, 2023.
  • Research and development costs for the three months ended March 31, 2024 were $272,000 as compared to $144,000 for the three months ended March 31, 2023.
  • Diluted loss and earnings per share for the three months ended March 31, 2024 and 2023 were $(0.07) and $0.03, respectively.

FDA Grants Orphan Drug Designation to 9MW2821

Retrieved on: 
星期二, 五月 7, 2024
Esophageal cancer, FDA, FTD, Orphan, Clinical trial, ODD, Patient, Policy, Food, Pharmaceutical industry

SHANGHAI, May 7, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its self-developed novel Nectin-4-targeting ADC (R&D code: 9MW2821) has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA), for the treatment of esophageal cancer.

Key Points: 
  • SHANGHAI, May 7, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its self-developed novel Nectin-4-targeting ADC (R&D code: 9MW2821) has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA), for the treatment of esophageal cancer.
  • The FDA grants Orphan Drug Designation to treatments for rare diseases in the United States that affect fewer than 200,000 patients.
  • Orphan Drug Designation offers policy benefits to drug developers, including as aid with medication development, tax credits for a part of clinical trial expenditures, and seven years of market exclusivity upon approval.
  • 9MW2821 was previously given Fast Track Designation (FTD) by the FDA for the treatment of advanced, recurrent, or metastatic esophageal squamous cell carcinoma.

BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

Retrieved on: 
星期五, 五月 3, 2024
University, Research and development, Radiation, Oncology, Research, Abstract, Immunotherapy, MD, University School, Cayetano Heredia University, Internet, Lung cancer, Radiation therapy, Johns Hopkins Hospital, International Association, Respiratory disease, Society, Lung, MD Anderson Cancer Center, Publication, Biomarker, Research institute, Esophageal cancer, Therapy, Cancer

The conference call and webinar will feature presentations by Key Opinion Leaders (KOLs) Trevor M. Feinstein, M.D.

Key Points: 
  • The conference call and webinar will feature presentations by Key Opinion Leaders (KOLs) Trevor M. Feinstein, M.D.
  • (MD Anderson Cancer Center), who will discuss below topics:
    Also featured will be a management discussion on technology platform and pipeline updates of SEED Therapeutics, BeyondSpring’s majority-owned molecular glue subsidiary.
  • He joined Piedmont Cancer Institute in 2011 and is the Director of Research at Piedmont Fayette Hospital.
  • Dr. Lin runs a translational research team that evaluates biomarkers for treatment response and disease outcomes after cancer therapy.